Tenax Therapeutics, Inc. (TENX) - 10-Q Summary
Business Context and Reporting Period
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, specifically pulmonary hypertension. The company is developing levosimendan (TNX-103) and has deprioritized imatinib. This report covers the quarterly period ended June 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(33.5) million | $(21.3) million |
| Net Loss Per Share (Basic/Diluted) | $(0.70) | $(0.56) |
| Operating Expenses | $35.4 million | $23.1 million |
| Research & Development (R&D) | $24.4 million | $11.8 million |
| Selling, General & Administrative (SG&A) | $11.0 million | $11.3 million |
| Interest Income | $1.8 million | $1.9 million |
| Cash and Cash Equivalents (End of Period) | $118.0 million | $105.5 million |
| Net Cash Used in Operating Activities | $(23.5) million | $(13.2) million |
| Net Cash Provided by Financing Activities | $43.9 million | $23.8 million |
| Total Liabilities | $8.1 million | $7.2 million |
| Working Capital | $113.6 million | $97.1 million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 58% year-over-year (YoY) to $33.5 million, driven primarily by a 107% increase in R&D expenses.
- R&D Expansion: R&D expenses rose to $24.4 million (from $11.8 million) due to the initiation of the global Phase 3 LEVEL-2 trial in December 2025 and continued costs for the LEVEL trial.
- Capital Raising via Warrants: Financing activities generated $43.9 million in cash, primarily from the exercise of warrants and pre-funded warrants ($43.8 million), compared to $23.8 million in the prior year period.
- Share Count Growth: Common shares outstanding increased from 9.3 million at December 31, 2025, to 31.9 million at June 30, 2026, largely due to warrant exercises.
Guidance, Outlook, and Risks
- Clinical Milestones: The company expects to report initial topline data for the Phase 3 LEVEL trial in August 2026. The LEVEL-2 trial enrollment is anticipated to complete by the end of 2027.
- Liquidity Outlook: Management believes existing cash ($118.0 million) plus subsequent warrant exercises ($8.1 million received post-period) are sufficient to fund operations through the second quarter of 2028.
- Future Capital Needs: The company will require substantial additional capital to finalize levosimendan development, commence commercialization, and potentially reinitiate imatinib development. Future funding may come from equity issuances, debt, or collaborations.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing which may cause dilution, and the potential failure to achieve regulatory approval. The company has an accumulated deficit of $401.0 million.
- Subsequent Events: Post-June 30, 2026, the company received $8.1 million from the exercise of 3.7 million pre-funded warrants and 1.8 million warrants.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $118 million cash balance to fund operations through Q2 2028, considering the high burn rate of $23.5 million over six months.
- Warrant Expiration: Review the terms of the August 2024 Warrants, which expire 30 trading days after the LEVEL trial topline data announcement (expected August 2026), creating a potential dilution event.
- Orion License Obligations: Confirm the status of milestone payments to Orion Corporation, including the $10 million FDA approval milestone and potential $45 million commercialization milestones.
- Stock-Based Compensation: Monitor the $23.9 million in unrecognized stock option compensation costs that will impact future expenses.
- Revenue Timeline: Assess the timeline for potential revenue generation, as the company currently has no product revenue and expects to incur losses for the foreseeable future.